GSK plc and Flagship Pioneering have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology. This alliance brings together GSK’s disease area expertise and development capability with Flagship’s ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make advances in healthcare. GSK and Flagship will initially fund up to $150 million upfron...